GlaxoSmithKline PLC — Director's Dealing 2017

Feb 21, 2017

GlaxoSmithKline plc (the ‘ Company ’)

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Sir Andrew Witty | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Executive Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 00 | 67,867
(Deferred) |
| | | £0.00 00 | 22,621
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 90,448 £0.00 00 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Sir Andrew Witty | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Executive Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 20 February 2017 under
the Company’s Deferred Annual Bonus Plan – Deferred
Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.3353 | 31,898
(Deferred) |
| | | £16.3353 | 10,633
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 42,531 £16.3353 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Ms E Walmsley | |
| --- | --- | --- | --- |
| b) | Position/status | CEO Designate | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 00 | 14,860
(Deferred) |
| | | £0.00 00 | 4,954
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 19,814 £0.00 00 | |
| e) | Date
of the transaction | 2017-02-21 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Ms E Walmsley | |
| --- | --- | --- | --- |
| b) | Position/status | CEO Designate | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 21 February 2017 under
the Company’s Deferred Annual Bonus Plan – Deferred
Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.35 00 | 6,986
(Deferred) |
| | | £16.35 00 | 2,330
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 9,316 £16.35 00 | |
| e) | Date
of the transaction | 2017-02-21 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Mr D S Redfern | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Strategy Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 00 | 12,115
(Deferred) |
| | | £0.00 00 | 4,039
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 16,154 £0.00 00 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Mr D S Redfern | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Strategy Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 2 0 February 2017 under the
Company’s Deferred Annual Bonus Plan – Deferred Bonus
and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.3425 | 5,809
(Deferred) |
| | | £16.3450 | 1,937
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 7,746 £16.3431 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Ms C Thomas | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Human Resources | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 00 | 7,517
(Deferred) |
| | | £0.00 00 | 2,506
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 10,023 £0.00 00 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Ms C Thomas | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Human Resources | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 20 February 2017 under
the Company’s Deferred Annual Bonus Plan – Deferred
Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.37 00 | 3,604
(Deferred) |
| | | £16.355 0 | 1,202
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 4,806 £16.3662 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Mr P C Thomson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Communications & Government Affairs | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 00 | 4,528
(Deferred) |
| | | £0.00 00 | 1,509
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 6,037 £0.00 00 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
(‘PCA’) — Name | Mr P C Thomson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Communications & Government Affairs | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3 . | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 2 0 February 2017 under the
Company’s Deferred Annual Bonus Plan – Deferred Bonus
and Matching Awards . | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.3450 | 2,171
(Deferred) |
| | | £16.3500 | 724
(Matching) |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 2,895 £16.3462 | |
| e) | Date
of the transaction | 2017-02-20 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

page break